Table 1.
Participants descriptive statistics
| IDIs | FGDs | ||
|---|---|---|---|
| Age | |||
| Gender | Female | 8 | 15 |
| Male | 5 | 13 | |
| Cancer diagnosis | Breast cancer | 8 | 4 |
| Chorio carcinoma | 5 | ||
| Kaposi’s Sarcoma | 2 | 1 | |
| Ovarian Carcinoma | 2 | ||
| Cervical Carcinoma | 2 | ||
| Oesophageal carcinoma | 2 | ||
| Colorectal carcinoma | 1 | 1 | |
| Pancreatic carcinoma | 1 | ||
| Small cell lung carcinoma | 1 | 1 | |
| Nasopahrgeal carcinoma | 1 | ||
| Sinonaso carcinoma | 2 | 1 | |
| Osteosarcoma | 2 | ||
| Rhabdosarcoma | 1 | ||
| Fibrosarcoma | 4 | ||
| Chemotherapy |
Cyclophosphamide, Adriamycin 5 fluoro-uracil (CAF) |
8 | 4 |
| Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide Vincristine (EMACO) | 5 | ||
| Bleomycin and Vinicristine (BV) | 2 | 1 | |
| 5 fluoro-uracil, Leucovorin and Oxaliplatin (FolFox-6) | 1 | ||
| Cisplatin and Etoposide | 1 | ||
| Gemicitabine, Bleomycin, Etoposide and Cisplatin | 1 | ||
| Cisplatin and Etoposide | 1 | ||
| Cisplatin and 5 Fluoro Uracil | 2 | ||
| Cisplatin and Paclitaxel | 3 | ||
| Doxorubicin, Vincristine, Cytarabine and Dounorubicin | 1 | ||
| Bleomycin, Vinicristine and Paclitaxel | 2 | ||
| Ifosphamide and Doxorubicin | 1 | ||
| Bleomycin, Etoposide and Cisplatin | 1 | ||
| Cisplatin and Doxorubicin | 2 | ||
| Oxaliplatin and Capecitabine | 1 | ||
| Vincristine,Adriamycin and Dacabazine | 1 | ||
| Gemicitabine and Docetaxel | 1 | ||
| Cyclophosphamide,Adriamycin, Vincristine and Prednisolone (CHOP) | 1 | ||
| Paclitaxel | 2 | ||